Transplantation proceedings · 2026
Safety and Efficacy of Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation for Salvage Therapy of Myelofibrosis.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wang Xiaojin, Fu Andie, Xu Bin, Wang Na, Yang Yang, Hong Zhenya, Huang Lifang, Xu Jinhuan, Cao Yang, Meng Fankai, Zhang Donghua, Zhang Yicheng
Аннотация
OBJECTIVE: To evaluate the efficacy and safety of reduced-intensity conditioning (RIC) allogeneic hematopoietic stem cell transplantation (allo-HSCT) for a salvage therapy of patients with myelofibrosis (MF).
METHODS: We conducted a retrospective study of 17 MF patients with poor performance status, refractory disease, or progressive disease who underwent RIC-allo-HSCT. Overall survival (OS), progression-free survival (PFS), hematopoietic reconstitution, the cumulative incidence of relapse and improvements in myelofibrosis and splenomegaly were analyzed.
RESULTS: All 17 patients received RIC regimens. The neutrophil and platelet engraftment rates were 94.1% and 88.2%, respectively, with median engraftment times of 16 days (range, 11-22 days) and 22 days (range, 10-148 days). The cumulative incidence of grade II-IV acute graft-versus-host disease (aGVHD) within 100 days post-transplant was 41.2%, and that of grade III-IV aGVHD was 17.6%. The overall incidence of chronic GVHD (cGVHD) was 35.3%. The reactivation rates of Epstein-Barr virus (EBV) and cytomegalovirus (CMV) were 47.1% and 29.4%, respectively. Before transplantation, there were 10 patients (58.8%) with MF-3 and splenomegaly. At six months after transplantation, the proportion of MF-3 decreased to 26.7%, MF-0 increased to 40.0%, and the proportion of splenomegaly decreased to 53.3%. As of the follow-up date, the proportion of MF-3 had decreased to 21.4%, MF-0 had increased to 57.1%, and all eight remaining patients with splenomegaly had shown varying degrees of spleen size reduction. The estimated 1-year OS and PFS were 88.2% (95% CI, 60.6%-96.9%) and 81.9% (95% CI, 53.8%-93.8%), and the estimated 3-year OS and PFS were 70.6% (95% CI, 26.0%-91.4%) and 65.5% (95% CI, 25.7%-87.7%), respectively.
CONCLUSION: RIC-allo-HSCT is a feasible and effective alternative for salvage therapy in MF patients.
METHODS: We conducted a retrospective study of 17 MF patients with poor performance status, refractory disease, or progressive disease who underwent RIC-allo-HSCT. Overall survival (OS), progression-free survival (PFS), hematopoietic reconstitution, the cumulative incidence of relapse and improvements in myelofibrosis and splenomegaly were analyzed.
RESULTS: All 17 patients received RIC regimens. The neutrophil and platelet engraftment rates were 94.1% and 88.2%, respectively, with median engraftment times of 16 days (range, 11-22 days) and 22 days (range, 10-148 days). The cumulative incidence of grade II-IV acute graft-versus-host disease (aGVHD) within 100 days post-transplant was 41.2%, and that of grade III-IV aGVHD was 17.6%. The overall incidence of chronic GVHD (cGVHD) was 35.3%. The reactivation rates of Epstein-Barr virus (EBV) and cytomegalovirus (CMV) were 47.1% and 29.4%, respectively. Before transplantation, there were 10 patients (58.8%) with MF-3 and splenomegaly. At six months after transplantation, the proportion of MF-3 decreased to 26.7%, MF-0 increased to 40.0%, and the proportion of splenomegaly decreased to 53.3%. As of the follow-up date, the proportion of MF-3 had decreased to 21.4%, MF-0 had increased to 57.1%, and all eight remaining patients with splenomegaly had shown varying degrees of spleen size reduction. The estimated 1-year OS and PFS were 88.2% (95% CI, 60.6%-96.9%) and 81.9% (95% CI, 53.8%-93.8%), and the estimated 3-year OS and PFS were 70.6% (95% CI, 26.0%-91.4%) and 65.5% (95% CI, 25.7%-87.7%), respectively.
CONCLUSION: RIC-allo-HSCT is a feasible and effective alternative for salvage therapy in MF patients.